Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC

There are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adjuvant Cancers Chemotherapy Lung Neoplasms

Age range

18 year–88 year

Sex eligibility

All sexes

Study type

Observational

About this study

We propose to retrospectively examine the Washington University School of Medicine experience on all patients receiving adjuvant chemotherapy between 2003 and 2005. We will retrospectively analyze the survival and outcomes in the lung cancer patients receiving adjuvant chemotherapy following surgical resection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients that received adjuvant chemotherapy
18-88 years

Exclusion criteria

Any patients that have not received adjuvant chemotherapy
Patients under 18 or over 88

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected Non Small Cell Lung Cancer

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Jun 8, 2007
Registry last updated: Aug 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed